Clinical Impact of Continuous Glucose Monitoring for 6–12 Months in Individuals with Type 2 Diabetes – A Retrospective, Chart-review Study from India
Jothydev Kesavadev, Jaikishan Agrawal, Arun Shankar, Banshi SabooAbstract
Background and Aim:
Real-world evidence remains scarce regarding the long-term impact of continuous glucose monitoring (CGM) in Asians with type 2 diabetes (T2D). This retrospective chart-review study evaluated the effectiveness of 6–12 months of CGM on glycated hemoglobin (HbA1c) and CGM metrics in Asians with T2D.
Methods:
Demographics, clinical, laboratory, and CGM data were extracted for individuals with T2D and baseline HbA1c 7%–12%. Co-primary endpoints were change in HbA1c and glucose management indicator (GMI) from baseline to 3–6 and 6–12 months of CGM initiation. Secondary endpoints included change in time in range (TIR) and coefficient of variation (%CV), and subgroup analysis of change in HbA1c by age, sex, body mass index, diabetes duration, and baseline HbA1c.
Results:
Eighty eligible individuals with T2D, mean (standard deviation [SD]) age 54.4 (11.9) years, 67.5% male, were enrolled. HbA1c significantly decreased by a mean (SD) of 0.39 (0.33) % at 3–6 months,
Conclusions:
In Asian individuals with T2D, CGM use was associated with improvement in HbA1c, GMI, TIR, and stable %CV at 6–12 months, with possible greater benefits in those with higher baseline HbA1c.